GMCI plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Non-small Cell Lung Cancer (nsclc)
-
Age: Between 18 years - 100 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1)Patients with Stage III/IV NSCLC on treatment with anti-PD-1/PD-L1 (ICI)+/ -chemotherapy. 2) Patients who have measurable disease including a lesion that is amenable to injection. 3) Patients who are able and willing to undergo a pre-treatment and on-treatment biopsy.
You may not be eligible for this study if the following are true:
-
1) Patients with a history of severe hypersensitivity reaction to ICI. 2) Patients who require ongoing therapy with systemic immunosuppressive drugs including systemic corticosteroids. 3) Patients with a history of active autoimmune disease requiring treatment in the past 2 years.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.